LI-FRAUMENI SYNDROME: AN OVERVIEW OF CANCER PREDISPOSITION AND MANAGEMENT STRATEGIES

Abstract

Li-Fraumeni syndrome (LFS) is a rare hereditary condition with a high predisposition to developing multiple types of cancer throughout life, often starting in childhood. This syndrome is predominantly caused by mutations in the TP53 gene, which encodes the p53 protein, essential for regulating the cell cycle and responding to cellular stress. A deficiency in p53 function leads to a loss of cellular surveillance, resulting in an increased predisposition to various cancers, including sarcomas, breast cancer, leukemias, and brain tumors. The identification of LFS is based on clinical criteria and is confirmed through genetic testing, which can be challenging due to variability in clinical presentation and overlap with other genetic syndromes. Managing the syndrome involves rigorous and continuous surveillance for early cancer detection, as well as genetic counseling to guide patients and their families about risks and monitoring strategies. Advances in genetic research have expanded the understanding of the molecular mechanisms of LFS and improved diagnostic criteria and therapeutic approaches. Despite challenges in diagnosis and management, the combination of early monitoring strategies and personalized interventions can significantly improve the prognosis and quality of life of individuals affected by Li-Fraumeni syndrome.